








Experiences of using routinely collected medical data in a cardiovascular safety trial?

lan Ford

Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit







Issues in clinical trials

- Study feasibility
- Recruitment
- Data capture
- QA/ monitoring
- Pharmacovigilance
- Long-term follow-up within and after trial
- Desire to do large simple trials
 - —Comparative safety
 - —Comparative efficacy





Data cleaning







eTRIALS: Trial Portals

15/04/2005 Demonstration e-Trial Jane Aziz

Main

Home Mailer Forum Contacts

Trial Site

Enter Subject

Study drug

Subject Status

Subject Data

Data Management

Data Summaries



This web portal provides an interactive demonstration of some of the e-solutions provided by the Robertson Centre to aid in Clinical Trial data management.

Please select an option from the menu on the left to view that application.

Site 1

Western Infirmary

Total Randomised:

First Subject Randomised: 06/04/2005 Last Subject Randomised: 14/04/2005 Site 2

Glasgow Royal Infirmary University NHS Trust

Total Randomised:

First Subject Randomised: N/A

Last Subject Randomised: N/A

Site 3

The Royal Hospital for Sick Children

Total Randomised:

First Subject Randomised: 14/04/2005 Last Subject Randomised: 14/04/2005

NHS

From conception to death...

- Mothers ante-natal records
- Maternity
- Neonatal record
- Register birth NHS number
- Register with GP CHI
- GP Appointments
- Dental Appointments
- Outpatients
- A&E attendance
- General hospital admission
- Prescribing
- Cancer registration
- Cancer treatment
- Community care
- Death



















Inclusion / Exclusion



- Inclusion
 - Patients with OA or RA taking NSAIDS (>90 days in previous year)
 - Aged 60 years or over
- Exclusion
 - History of vascular disease

Design





Endpoints



- Primary
 - -CV death, MI, stroke
- Secondary
 - GI hospitalisation

Design



- Non-inferiority trial
 - Non-inferiority limit set at HR = 1.3
- Pragmatic trial
 - PROBE design

Design



- Sponsor: University of Dundee
- CI: Prof Tom MacDonald
- Target recruits: 13,682 (611 primary endpoints)
- Recruitment from primary care
- Initial Countries: Scotland, Denmark

Committees



- Executive
- Steering
- IDMC
- CV endpoints
- Gl endpoints

Processes (Scotland)




- Pre-screen GP electronic records
- Invite potentially eligible patients for screening
- Consent
- Check inclusion/exclusion
- Record baseline characteristics on eCRF
- Randomise
- Prescribe
- Follow up off-line

Data Collections systems



- Primary Care
 - Electronic search tool
 - Data extract to upload prescription data
- Lab data
- Randomisation
 - IVRS
- E-CRF
 - Screening
- Follow-up data
 - Record linkage (deaths, hospital admissions, cancer registry)
- Pharmacovigilance



Why e-Searching



Pros

- Reduces the amount of manual review
- Tracks each stage in the screening process
- Metrics available earlier in the trial

Cons

 Many varieties of GP system that the software has to work in!

START



- Streamlined Trial Adaptable Recruitment Toolset
 - Identify potential participants
 - Facilitates letter of invitation generation
 - Track screening process
 - Generate files for upload





€ Scot e-CRF						_ □ 🛚		
😤 Home 🛿 😤 Participant Data	ta 🕜 Help 🤟 Exit					-		
Consent Personal Details De	emographics Medications	Cardio History GI History	Other History	Measurements	Inclusion Criteria	Exclusion Criteria Checklist		
Demographics								
Site: 109 Participant N	Number: 001 Partici	pant Initials: AA	Visit Date:	✓ 01 Novemb	oer 2007 💌	Screening Visit		
1. Date of Birth? ☑31 December 1955 ☑								
2. Gender?	1ale 🔘 Female							
3. Race? OWhite Asian Afro-Caribbean Oriental								
⊙ Ot	Other Specify hispanic							
4. Smoking History? 🔘 Cu	urrent							
● Fc	ormer (i) Approx	number of years smoked?	15]			
O Ne	lever (ii) Did you	smoke Cigarettes?	Ye	s 🔘 No				
	(iii) Average	number per day?	20]			
	urrent							
Consumption?	omier	rinking, average no of units p						
O Ne	lever (ii) Approx	number of years since stopp	ed? 2					
	(iii) Main re	ason for stopping?	O Do	ctor's advice 🔘	Personal concern	about health		
			⊙ Oth	ner Specify	Alcoholic			
Save								
I								


Lab data in Scotland



- Lab data in Scotland
 - Via hospital labs
 - SCI store(s)
- Issues:
 - Lots of negotiation!

e-CRF – Randomisation





IVRS



Using SCOT IVRS

- Dial freephone number
- Enter study site and participant ID (screening number)
- Stratification by indication (RA or OA) and screening NSAID

Event follow-up



- Information Services Division
- •Electronic linkage to Scottish national linked datasets of hospital admissions, incident cancers and deaths
- Historical approach
 - Link on DOB, name, place of residence
 - probabilistic matching
- Current/ Future
 - Unique identifier matching (CHI)

Follow up datasets



 Datasets transferred routinely to the Data Centre from ISD:

SMR 01 General acute inpatient and day case

discharges

SMR 04 Psychiatric and mental handicap

hospitals and units: Admissions,


residents and discharges

SMR 06 Scottish cancer registrations

– GRO(S) death registrations




GP Reminder - email



GP: Upload Prescribing Data





GP Follow up- Via web portal



- Every 2 months
 - Adverse Events leading to discontinuation of randomised study treatment
 - Serious Adverse Events
 - Regulatory requirement


Web Portal - GP Follow-up scot

Home > Subject Data > Follow-up Visits > Current Subject Status

urrent Subject Status ·		
e: 001 Subject: 001 Subject Initials: TST		-up Visit 18 25/04/2008
Yes answer to any of the following questions, indicates a change to the subject st	atus	
Has subject experienced a new treatment related Adverse Event, that has come to your attention?	○ Yes	○ No
Has subject experienced a new SAE, that has come to your attention?	O Yes	○ No
Has the subject discontinued the study treatment or permanently discontinued from the trial?	○ Yes	○ No
Has there been a change to the subject's contact details?	O Yes	○ No
	<< Previous	Save
	e: 001 Subject: 001 Subject Initials: TST Yes answer to any of the following questions, indicates a change to the subject state Has subject experienced a new treatment related Adverse Event, that has come to your attention? Has subject experienced a new SAE, that has come to your attention? Has the subject discontinued the study treatment or permanently discontinued from the trial?	e: 001 Subject: 001 Subject Initials: TST Follow-up Date: Yes answer to any of the following questions, indicates a change to the subject status Has subject experienced a new treatment related Adverse Event, that has come to your attention? Has subject experienced a new SAE, that has come to your attention? Has the subject discontinued the study treatment or permanently discontinued from the trial? Has there been a change to the subject's contact details? O Yes

Pharmacovigilance






SAE Reporting



- Report to Sponsor and Pfizer
 - Pfizer insist on communicating by fax!!
- Report to Ethics and Regulatory authorities



Web portal



- Secure controlled-access
- Demonstration version for training
- •Components:
 - Electronic data capture (e-CRF)
 - Source document scan/ upload
 - Endpoint Committee Review and Adjudication
 - Reports
 - Documentation library
 - Data upload interface for primary care datasets
 - Automated e-mail reminders to GPs
 - Live study metrics

Challenges...



- Heterogeneity of primary care and lab systems
- Requirements for SAE reporting
 - primary care investigator reporting
 - duplicate reporting resolution
 - reporting of relatedness etc
 - >> Do we need this in Phase IV??
- Potential need for adjudication of events
 - non-inferiority studies subject to greater event quality scrutiny
 - uncertainty about quality of event coding in routinely collected health records

